UNIVERSITY OF TABUK

Checkpoint Inhibitors Show Promise for HIV-Positive Cancer Patients Across Multiple Studies

- Multiple recent studies demonstrate that immune checkpoint inhibitors are safe and effective for HIV-positive cancer patients, with response rates and survival outcomes comparable to HIV-negative patients. - Research spanning melanoma, lung cancer, and other malignancies shows no significant differences in adverse event rates between HIV-positive and HIV-negative patients receiving checkpoint inhibitor therapy. - Evidence suggests checkpoint inhibitors may also contribute to HIV cure research, with some studies indicating potential for reducing viral reservoirs and delaying viral rebound. - Findings support treating well-controlled HIV patients similarly to the general cancer population and highlight the need for greater inclusion in clinical trials.